Status:
COMPLETED
Timed-Sequential Induction in CBF-AML
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
Acute Leukemia French Association
French Innovative Leukemia Organisation
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
18-60 years
Phase:
PHASE3
Brief Summary
Core binding factor (CBF) acute myeloid leukemias (AML) include AMLs carrying the t(8;21) translocation as well as AMLs carrying either the inversion of chromosome 16 or translocation t(16;16). CBF-AM...
Detailed Description
Core binding factor (CBF) acute myeloid leukemias (AML) include AMLs carrying the t(8;21) translocation as well as AMLs carrying either the inversion of chromosome 16 or translocation t(16;16). CBF-AM...
Eligibility Criteria
Inclusion
- Patients aged 18-60 years.
- With a newly-diagnosed de novo or therapy-related CBF-AML defined
Exclusion
- No previously treated with any anti-leukemic agent.
- No presenting any diagnosis of uncontrolled or metastatic tumor.
- OMS performance status \< 2,
- Absence of uncontrolled severe infection,
- AST and ALT 2.5 x ULN,
- Total bilirubin 1.5 x ULN,
- Serum creatinine 1.5 x ULN
Key Trial Info
Start Date :
July 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00428558
Start Date
July 1 2007
End Date
June 1 2011
Last Update
December 20 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service Hematologie Oncologie
Nîmes, France, 30029